This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Monopar Therapeutics Inc (MNPR) and Bio-Techne (TECH)

Tipranks - Tipranks - Tue Jun 30, 4:36AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medtronic (MDT), Monopar Therapeutics Inc (MNPR) and Bio-Techne (TECH) with bullish sentiments.

End of Quarter Sale - 70% Off

Medtronic (MDT)

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Medtronic on June 26 and set a price target of $102.00. The company’s shares closed last Friday at $80.98.

According to TipRanks.com, Biegelsen is a 3-star analyst with an average return of 2.1% and a 49.9% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Inspire Medical Systems, and Zimmer Biomet Holdings. ;'>

Currently, the analyst consensus on Medtronic is a Moderate Buy with an average price target of $97.90, implying a 22.6% upside from current levels. In a report issued on June 19, TipRanks – Google also upgraded the stock to Buy with a $90.00 price target.

See today’s best-performing stocks on TipRanks >>

Monopar Therapeutics Inc (MNPR)

Barclays analyst Etzer Darout maintained a Buy rating on Monopar Therapeutics Inc today and set a price target of $125.00. The company’s shares closed last Friday at $87.68.

According to TipRanks.com, Darout is a 5-star analyst with an average return of 29.4% and a 61.6% success rate. Darout covers the Healthcare sector, focusing on stocks such as First Tracks Biotherapeutics Inc, Protagonist Therapeutics, and Iovance Biotherapeutics. ;'>

Monopar Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $111.89.

Bio-Techne (TECH)

In a report issued on June 26, Brandon Couillard from Wells Fargo maintained a Buy rating on Bio-Techne, with a price target of $62.00. The company’s shares closed last Friday at $71.00.

According to TipRanks.com, Couillard is a 5-star analyst with an average return of 17.8% and a 62.0% success rate. Couillard covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Bio-Rad Laboratories, and Guardant Health. ;'>

Bio-Techne has an analyst consensus of Hold, with a price target consensus of $65.36, a -7.7% downside from current levels. In a report issued on June 25, TipRanks – PerPlexity also upgraded the stock to Buy with a $67.00 price target.

Read More on MDT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).